Bristol-Myers Squibb and Pfizer announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial according to patient age in patients with nonvalvular atrial fibrillation (NVAF).
Your search for Warfarin returned 94 results
Bristol-Myers Squibb and Pfizer announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis (apixaban) vs. warfarin to blood pressure control in patients with nonvalvular atrial fibrillation (NVAF).
The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).
Findings from a recent study suggests that clinical and genetic factors affecting warfarin dose requirements differ by race.
“The elevation in INR can be explained by the inhibition of CYP2C9 by cannabis use causing decreased metabolism of warfarin,” the authors explained.
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
The ROCKET-AF study provided the primary data to support the 2011 approval of Xarelto.
Rivaroxaban, a non-vitamin K antagonist (VKA) oral anticoagulant, was found to have better persistence and lower discontinuation rates than, the VKA warfarin and the non-VKA, dabigatran.
A recent clinical study found that combining genetic data with clinical information to determine initial warfarin dosing was no more effective than using only clinical information, according to the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.
The patient in this case had been well-controlled on warfarin therapy for over 5 years following mitral valve replacement.